Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Kalaris Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- −21 vs. Q4 2024
- Shares held
- 13.9M
- +11.7M (+543.4%) vs. Q4 2024Converted for a 1-for-23 split
- Total value
- $111.4M
- +$90.8M (+439.3%) vs. Q4 2024
- New holders
- 2
- 12 more added
- Sold out
- 23
- 10 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KLRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $73.4M |
| Q1 2026 | 58 | $107.2M |
| Q4 2025 | 51 | $151.9M |
| Q3 2025 | 32 | $76.4M |
| Q2 2025 | 30 | $35.7M |
| Q1 2025 | 32 | $111.4M |
| Q4 2024 | 53 | $20.7M |
| Q3 2024 | 60 | $36.3M |
| Q2 2024 | 72 | $33.9M |
| Q1 2024 | 77 | $36.4M |
| Q4 2023 | 82 | $28.5M |
| Q3 2023 | 90 | $115.5M |
| Q2 2023 | 94 | $183.6M |
| Q1 2023 | 89 | $156.0M |
| Q4 2022 | 86 | $193.1M |
| Q3 2022 | 87 | $293.7M |
| Q2 2022 | 84 | $109.6M |
| Q1 2022 | 84 | $184.1M |
| Q4 2021 | 84 | $329.4M |
| Q3 2021 | 80 | $640.3M |
| Q2 2021 | 84 | $521.8M |
| Q1 2021 | 75 | $624.4M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Kalaris Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Barclays PLC | 1 | $8 | 0.00% | +1 | New |
| EverSource Wealth Advisors, LLC | 30 | $241 | 0.00% | −0−0.7% | ReducedConverted for a 1-for-23 split |
| Farther Finance Advisors, LLC | 33 | $264 | 0.00% | −0−1.3% | ReducedConverted for a 1-for-23 split |
| Parallel Advisors, LLC | 49 | $393 | 0.00% | −1−1.6% | ReducedConverted for a 1-for-23 split |
| BNP Paribas Arbitrage, SA | 127 | $1.02K | 0.00% | −3,132−96.1% | ReducedConverted for a 1-for-23 split |
| Coldstream Capital Management Inc | 208 | $1.67K | 0.00% | +208 | New |
| JPMorgan Chase & Co | 295 | $2.37K | 0.00% | −60−16.8% | ReducedConverted for a 1-for-23 split |
| Federated Hermes, Inc. | 634 | $5.09K | 0.00% | +59+10.4% | AddedConverted for a 1-for-23 split |
| Morgan Stanley | 1,296 | $10.4K | 0.00% | +299+30.0% | AddedConverted for a 1-for-23 split |
| Tower Research Capital LLC (TRC) | 1,434 | $11.5K | 0.00% | +675+89.0% | AddedConverted for a 1-for-23 split |
| Bank of America Corp | 5,424 | $43.6K | 0.00% | +4,438+450.1% | AddedConverted for a 1-for-23 split |
| FMR LLC | 7,806 | $62.7K | 0.00% | −6,034−43.6% | ReducedConverted for a 1-for-23 split |
| UBS Group AG | 9,261 | $74.4K | 0.00% | +3,804+69.7% | AddedConverted for a 1-for-23 split |
| State Street Corp | 10,710 | $86.0K | 0.00% | 00.0% | UnchangedConverted for a 1-for-23 split |
| Susquehanna International Group, LLP | 13,796 | $110.8K | 0.00% | +10,153+278.7% | AddedConverted for a 1-for-23 split |
| Marshall Wace, LLP | 14,115 | $113.3K | 0.00% | 00.0% | UnchangedConverted for a 1-for-23 split |
| Squarepoint Ops LLC | 14,587 | $117.1K | 0.00% | −106−0.7% | ReducedConverted for a 1-for-23 split |
| Millennium Management LLC | 16,582 | $133.2K | 0.00% | −115,322−87.4% | ReducedConverted for a 1-for-23 split |
| RBF Capital, LLC | 17,391 | $139.7K | 0.01% | 00.0% | UnchangedConverted for a 1-for-23 split |
| Renaissance Technologies LLC | 19,251 | $154.6K | 0.00% | +2,748+16.7% | AddedConverted for a 1-for-23 split |
| Woodline Partners LP | 21,519 | $172.8K | 0.00% | +1,873+9.5% | AddedConverted for a 1-for-23 split |
| Two Sigma Advisers, LP | 21,581 | $173.3K | 0.00% | 00.0% | UnchangedConverted for a 1-for-23 split |
| Geode Capital Management, LLC | 26,787 | $215.2K | 0.00% | +1,362+5.4% | AddedConverted for a 1-for-23 split |
| BlackRock, Inc. | 27,514 | $220.9K | 0.00% | 00.0% | UnchangedConverted for a 1-for-23 split |
| Redmile Group, LLC | 82,955 | $666.1K | 0.06% | 00.0% | UnchangedConverted for a 1-for-23 split |
| Vanguard Group Inc | 115,086 | $924.1K | 0.00% | 00.0% | UnchangedConverted for a 1-for-23 split |
| EcoR1 Capital, LLC | 201,718 | $1.62M | 0.10% | +183,949+1,035.2% | AddedConverted for a 1-for-23 split |
| Siren, L.L.C. | 282,586 | $2.27M | 0.13% | −4,247−1.5% | ReducedConverted for a 1-for-23 split |
| Tang Capital Management LLC | 309,221 | $2.48M | 0.14% | +285,210+1,187.8% | AddedConverted for a 1-for-23 split |
| Octagon Capital Advisors LP | 481,000 | $3.86M | 0.84% | −6,609−1.4% | ReducedConverted for a 1-for-23 split |
| Gilead Sciences, Inc. | 723,273 | $5.81M | 0.49% | 00.0% | UnchangedConverted for a 1-for-23 split |
| Samsara BioCapital, LLC | 11,448,081 | $91.9M | 16.39% | +11,444,501+319,694.3% | AddedConverted for a 1-for-23 split |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −28,888−100.0% | Sold outConverted for a 1-for-23 split |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −11,591−100.0% | Sold outConverted for a 1-for-23 split |
| BML Capital Management, LLC | 0 | $0 | 0.00% | −8,011−100.0% | Sold outConverted for a 1-for-23 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −6,943−100.0% | Sold outConverted for a 1-for-23 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −6,674−100.0% | Sold outConverted for a 1-for-23 split |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −5,355−100.0% | Sold outConverted for a 1-for-23 split |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −3,033−100.0% | Sold outConverted for a 1-for-23 split |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −2,630−100.0% | Sold outConverted for a 1-for-23 split |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −2,157−100.0% | Sold outConverted for a 1-for-23 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −2,025−100.0% | Sold outConverted for a 1-for-23 split |
| Lido Advisors, LLC | 0 | $0 | 0.00% | −1,710−100.0% | Sold outConverted for a 1-for-23 split |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −1,416−100.0% | Sold outConverted for a 1-for-23 split |
| HRT Financial LP | 0 | $0 | 0.00% | −1,373−100.0% | Sold outConverted for a 1-for-23 split |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −1,169−100.0% | Sold outConverted for a 1-for-23 split |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −701−100.0% | Sold outConverted for a 1-for-23 split |
| PFG Investments, LLC | 0 | $0 | 0.00% | −696−100.0% | Sold outConverted for a 1-for-23 split |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −632−100.0% | Sold outConverted for a 1-for-23 split |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −518−100.0% | Sold outConverted for a 1-for-23 split |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −161−100.0% | Sold outConverted for a 1-for-23 split |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −130−100.0% | Sold outConverted for a 1-for-23 split |
| Citigroup Inc | 0 | $0 | 0.00% | −7−100.0% | Sold outConverted for a 1-for-23 split |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-23 split |
| CWM, LLC | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-23 split |